StockData
Veracyte, Inc. logo

Veracyte, Inc. (VCYT) stock

VCYTNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 16/3034% below fair value
$24.23+0.22 (+0.92%)

Close on Nov 17, 2026Market cap $1.95BP/E 17.3Yield –

Veracyte ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Veracyte's ebitda for the twelve months ending Jun 30, 2026 was $126.60M, up 243.9% year over year. For fiscal 2025 it was $79.19M, up 100.0% from the year before. The highest annual figure on record is $79.19M in fiscal 2025.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025$79.19M+100.0%
FY2024Dec 31, 2024$39.60M–
FY2023Dec 31, 2023-$58.61M–
FY2022Dec 31, 2022-$15.15M–
FY2021Dec 31, 2021-$62.31M–
FY2020Dec 31, 2020-$27.45M–
FY2019Dec 31, 2019-$11.01M–
FY2018Dec 31, 2018-$18.31M–
FY2017Dec 31, 2017-$22.70M–
FY2016Dec 31, 2016-$25.29M–
FY2015Dec 31, 2015-$31.21M–
FY2014Dec 31, 2014-$27.83M–
FY2013Dec 31, 2013-$22.17M–
FY2012Dec 31, 2012-$18.22M–
FY2011Dec 31, 2011-$14.66M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$27.82M+12487.3%
Q1 FY2026Mar 31, 2026$28.08M+239.7%
Q4 FY2025Dec 31, 2025$42.49M+307.5%
Q3 FY2025Sep 30, 2025$28.21M+57.7%
Q2 FY2025Jun 30, 2025$221.00K-97.9%
Q1 FY2025Mar 31, 2025$8.27M+785.0%
Q4 FY2024Dec 31, 2024$10.43M–
Q3 FY2024Sep 30, 2024$17.90M–
Q2 FY2024Jun 30, 2024$10.34M–
Q1 FY2024Mar 31, 2024$934.00K–
Q4 FY2023Dec 31, 2023-$29.17M-2667.9%
Q3 FY2023Sep 30, 2023-$24.42M–
Q2 FY2023Jun 30, 2023-$1.19M–
Q1 FY2023Mar 31, 2023-$3.83M–
Q4 FY2022Dec 31, 2022$1.14M–
Q3 FY2022Sep 30, 2022-$3.36M–
Q2 FY2022Jun 30, 2022-$4.24M–
Q1 FY2022Mar 31, 2022-$8.69M–
Q4 FY2021Dec 31, 2021-$5.93M–
Q3 FY2021Sep 30, 2021-$10.54M–
Q2 FY2021Jun 30, 2021-$2.97M–
Q1 FY2021Mar 31, 2021-$42.87M–
Q4 FY2020Dec 31, 2020-$6.05M–
Q3 FY2020Sep 30, 2020-$2.08M–
Q2 FY2020Jun 30, 2020-$9.09M–
Q1 FY2020Mar 31, 2020-$10.23M–
Q4 FY2019Dec 31, 2019-$6.92M–
Q3 FY2019Sep 30, 2019-$796.00K–
Q2 FY2019Jun 30, 2019-$2.18M–
Q1 FY2019Mar 31, 2019-$1.12M–
Q4 FY2018Dec 31, 2018-$2.09M–
Q3 FY2018Sep 30, 2018-$3.32M–
Q2 FY2018Jun 30, 2018-$4.93M–
Q1 FY2018Mar 31, 2018-$7.98M–
Q4 FY2017Dec 31, 2017-$5.04M–
Q3 FY2017Sep 30, 2017-$5.38M–
Q2 FY2017Jun 30, 2017-$5.67M–
Q1 FY2017Mar 31, 2017-$6.62M–
Q4 FY2016Dec 31, 2016-$2.76M–
Q3 FY2016Sep 30, 2016-$3.99M–

More Veracyte figures

See a number that looks wrong?